Ensign Peak Advisors
ESPR

Ensign Peak Advisors’s Esperion Therapeutics ESPR Stock Holding History

Ensign Peak Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-133,150
Closed -$666K – 2220
2021
Q4 		$666K Buy
+133,150
New +$1.07M ﹤0.01% 1491
2020
Q4 		– Sell
-21,855
Closed -$812K – 1866
2020
Q3 		$812K Sell
21,855
-3,590
-14% -$142K ﹤0.01% 1397
2020
Q2 		$1.31M Sell
25,445
-3,320
-12% -$139K ﹤0.01% 1179
2020
Q1 		$908K Sell
28,765
-7,187
-20% -$379K ﹤0.01% 1205
2019
Q4 		$2.14M Buy
+35,952
New +$1.62M 0.01% 1028

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Ensign Peak Advisors's ESPR Position: Q1 2022 in Review

Ensign Peak Advisors sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 133,150 shares — an estimated $666K sold.

Ensign Peak Advisors first reported a position in ESPR in Q4 2019 and held it in 5 quarters. The position peaked at $2.14M in Q4 2019. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Ensign Peak Advisors reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 133,150 Esperion Therapeutics shares in Q1 2022, an estimated $666K.
  • Ensign Peak Advisors first reported a position in Esperion Therapeutics in Q4 2019 and held it in 5 quarters.
  • Ensign Peak Advisors's Esperion Therapeutics position peaked at $2.14M in Q4 2019.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Ensign Peak Advisors's 13F filing for Q1 2022, filed 16 May 2022.